Regeneron says Pasatru shows zero new heterotopic ossification lesions in FOP patients during OPTIMA trial extension

Regeneron announced that Pasatru (garetosmab-grts) demonstrated zero new heterotopic ossification (HO) lesions in adult fibrodysplasia ossificans progressiva (FOP) patients during the OPTIMA trial extension, with 84-week findings showing no new HO lesions from week 56 to week 84, confirming sustained efficacy in halting rogue bone growth.

Detected & updated continuously · Source: Nebula